UDCA for disease modification
Testing approved liver drug for Parkinson’s disease modification.
AUDIO VERSION AVAILABLE.
Testing approved liver drug for Parkinson’s disease modification.
AUDIO VERSION AVAILABLE.
First reprogrammed stem cell trial has begun in Japan
PARP ensyme as an important target for disease modification
Neuroprotective evidence in antidiabetic drug NLY01
AUDIO VERSION AVAILABLE.
Regeneration of the axon no longer dismissed as impossible.
AUDIO VERSION AVAILABLE.
GSL reduction as a potential target for disease modification